Hidradenitis suppurativa (HS) is a chronic autoinflammatory condition affecting the skin, the genetic mechanisms of which are not well understood. A group of researchers set out to explore the genetic background of familial HS by performing whole-exome sequencing on genomic DNA from patients.
Veradermics Inc. raised $256.3 million from an IPO on the New York Stock Exchange Feb. 4. The proceeds will fund three ongoing phase II/III clinical trials of VDPHL-01, its novel oral formulation of Rogaine (minoxidil) to treat pattern hair loss in men and women.
Amgen Inc. quit a development deal with Kyowa Kirin Co. Ltd., returning global rights for rocatinlimab, Kyowa Kirin’s T-cell rebalancing therapy being investigated for moderate to severe atopic dermatitis.
Amgen Inc. quit a development deal with Kyowa Kirin Co. Ltd., returning global rights for rocatinlimab, Kyowa Kirin’s T-cell rebalancing therapy being investigated for moderate to severe atopic dermatitis.
Citing the “totality of data,” Sanofi SA plans to file global regulatory submissions this year for amlitelimab in atopic dermatitis, despite mixed results from two additional phase III trials testing the OX40-ligand (OX40L) inhibitor the pharma firm has been positioning as a potential successor to its Regeneron Pharmaceuticals Inc.-partnered blockbuster, Dupixent (dupilumab).
Corvus Pharmaceuticals Inc. rolled out new positive data to prove its thesis on the value of blocking IL-2-inducible T-cell kinase in atopic dermatitis (AD), and the company’s first-in-class approach “could shake up cancer and autoimmune disorders,” Wainwright analyst Swayampakula Ramakanth said when he started coverage Jan. 2.
Atopia Therapeutics SA has reported new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis.
Takeda Pharmaceuticals Co. Ltd.’s oral tyrosine kinase 2 inhibitor, zasocitinib (TAK-279), met the co-primary endpoints and all ranked secondary endpoints in two pivotal phase III studies in patients with moderate to severe plaque psoriasis.
Hisamitsu Pharmaceutical Co. Inc. President and CEO Kazuhide Nakatomi is leading a management buyout to take the company private, citing mounting drug pricing pressures and tougher listing requirements on the Tokyo Stock Exchange.
Enanta Pharmaceuticals Inc. has announced a new immunology program and updated progress in its immunology pipeline. The company’s new program is focused on developing oral MRGPRX2 inhibitors for type 2 immune driven diseases, with an initial focus on chronic spontaneous urticaria and other mast cell-driven diseases.
RSS
